{"id":114815,"date":"2019-06-11T12:14:18","date_gmt":"2019-06-11T04:13:28","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/114815\/"},"modified":"2019-06-11T12:13:29","modified_gmt":"2019-06-11T04:13:29","slug":"85ee0027ac","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/114815\/","title":{"rendered":"\u76ae\u8d28\u6fc0\u7d20\u662f\u5426\u4f1a\u5f71\u54cd\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7684\u7597\u6548\uff1f"},"content":{"rendered":"
\n
<\/section>\n
\n
\n
\n
\n
\n
\n
\n

1<\/strong><\/em><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u76ae\u8d28\u6fc0\u7d20\u662f\u80bf\u7624\u79d1\u7684\u5e38\u7528\u836f<\/span><\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

\u5bf9\u4e8e\u80bf\u7624\u79d1\uff0c\u76ae\u8d28\u6fc0\u7d20\u662f\u4e00\u79cd\u5f88\u91cd\u8981\u7684\u836f\u7269\uff0c\u5b83\u5177\u6709\u6297\u708e\u3001\u6297\u8fc7\u654f\u3001\u6297\u4f11\u514b\u3001\u6297\u6bd2\u7d20\u3001\u5f71\u54cd\u4ee3\u8c22\u7b49\u4f5c\u7528\uff0c\u53ef\u4ee5\u7528\u4e8e\u67d0\u4e9b\u80bf\u7624\u7684\u6297\u80bf\u7624\u6cbb\u7597\u6216\u8f85\u52a9\u6297\u80bf\u7624\u6cbb\u7597\uff0c\u5e76\u4e14\u88ab\u5e7f\u6cdb\u7528\u4e8e\u9884\u9632\u548c\u51cf\u8f7b\u5316\u7597\u836f\u7269\u7684\u4e0d\u826f\u53cd\u5e94\u3002<\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

\u80bf\u7624\u75c5\u4eba\u5728\u653e\u5316\u7597\u8fc7\u7a0b\u4e2d\u6076\u5fc3\u5455\u5410\u7684\u53d1\u751f\u7387\u7ea6\u4e3a 70%-80%\uff0c\u4e3a\u4e86\u63a7\u5236\u548c\u6539\u5584\u6076\u5fc3\u5455\u5410\uff0cNCCN\u3001ASCO \u53ca\u6211\u56fd\u6b62\u5410\u6307\u5357\u5747\u63a8\u8350\u5728\u4f7f\u7528\u6b62\u5410\u836f NK-1 \u53d7\u4f53\u62ee\u6297\u5242\u548c 5-HT3 \u53d7\u4f53\u62ee\u6297\u5242\u7684\u57fa\u7840\u4e0a\u8054\u5408\u4f7f\u7528\u5730\u585e\u7c73\u677e\uff0c\u53ef\u6709\u6548\u63a7\u5236\u6076\u5fc3\u5455\u5410\uff0c\u4e14\u5bf9\u52a0\u5f3a\u6cbb\u7597\u5ef6\u8fdf\u6027\u5455\u5410\u6548\u679c\u66f4\u4f73\u3002<\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n

\u5728\u4f7f\u7528\u57f9\u7f8e\u66f2\u585e\u65f6\uff0c\u9884\u670d\u5730\u585e\u7c73\u677e\u53ef\u4ee5\u964d\u4f4e\u76ae\u80a4\u53cd\u5e94\u7684\u53d1\u751f\u7387\u548c\u4e25\u91cd\u7a0b\u5ea6\u3002\u7ed9\u836f\u65b9\u6cd5\u4e3a\u7ed9\u836f\u524d\u4e00\u5929\u3001\u7ed9\u836f\u5f53\u5929\u3001\u7ed9\u836f\u540e\u4e00\u5929\u5206\u522b\u53e3\u670d\u5730\u585e\u7c73\u677e 4 mg\uff0c\u6bcf\u65e5 2 \u6b21\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n

\u5728\u4f7f\u7528\u7d2b\u6749\u9187\u7c7b\u836f\u7269\u65f6\uff0c\u9884\u670d\u5730\u585e\u7c73\u677e\u53ef\u4ee5\u964d\u4f4e\u52a9\u6eb6\u5242\u3001\u589e\u6eb6\u5242\u53ca\u7d2b\u6749\u9187\u672c\u8eab\u5bfc\u81f4\u7684\u8fc7\u654f\u53cd\u5e94\u7684\u53d1\u751f\u7387\u548c\u4e25\u91cd\u7a0b\u5ea6\u3002\u4e09\u5468\u7597\u7ed9\u836f\u65b9\u6cd5\u4e3a:<\/span>
<\/p>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n

\u5bf9\u4e8e\u7d2b\u6749\u9187\u6ce8\u5c04\u6db2\u5728\u7528\u836f\u524d 12 \u5c0f\u65f6\u548c\u7528\u836f\u524d 6 \u5c0f\u65f6\u5404\u670d\u7528\u5730\u585e\u7c73\u677e 20 mg\uff1b<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n

\u5bf9\u4e8e\u591a\u897f\u4ed6\u8d5b\u6ce8\u5c04\u6db2\u5728\u7ed9\u836f\u524d\u4e00\u5929\u3001\u7ed9\u836f\u5f53\u5929\u3001\u7ed9\u836f\u540e\u4e00\u5929\u5206\u522b\u53e3\u670d\u5730\u585e\u7c73\u677e 8 mg\uff0c\u6bcf\u65e5 2 \u6b21\uff1b<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n

\u5bf9\u4e8e\u7d2b\u6749\u9187\u8102\u8d28\u4f53\u6ce8\u5c04\u6db2\uff0c\u5c5e\u4e8e\u8102\u8d28\u4f53\u5242\u578b\u7684\u7d2b\u6749\u9187\uff0c\u4e0d\u9700\u8981\u6fc0\u7d20\u9884\u5904\u7406\uff0c\u4f46\u662f\u51fa\u4e8e\u8c28\u614e\u8003\u8651\uff0c\u5efa\u8bae\u6309\u7167\u8bf4\u660e\u4e66\u5728\u7ed9\u836f\u524d 30 \u5206\u949f\u7ed9\u4e88 5-10 mg \u5730\u585e\u7c73\u677e\u3002<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n

\u5728\u4f7f\u7528\u5229\u59a5\u6614\u5355\u6297\u65f6\uff0c\u5982\u679c\u6240\u4f7f\u7528\u7684\u6cbb\u7597\u65b9\u6848\u4e0d\u5305\u62ec\u76ae\u8d28\u6fc0\u7d20\uff0c\u9700\u8981\u4f7f\u7528\u7cd6\u76ae\u8d28\u6fc0\u7d20\u8fdb\u884c\u9884\u5904\u7406\uff0c\u4ee5\u51cf\u5c11\u6025\u6027\u8f93\u6db2\u53cd\u5e94\u7684\u75c7\u72b6\u548c\u4f53\u5f81\u4ee5\u53ca\u8d85\u654f\u53cd\u5e94\u548c\u901f\u53d1\u8fc7\u654f\u53cd\u5e94\u7684\u53d1\u751f\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

\u9664\u4e86\u4e0a\u8ff0\u7528\u9014\u4e4b\u5916\uff0c\u76ae\u8d28\u6fc0\u7d20\u8fd8\u88ab\u7528\u4e8e\u8f85\u52a9\u6297\u80bf\u7624\u6cbb\u7597\uff0c\u4ee5\u89e3\u9664\u3001\u7f13\u89e3\u80bf\u7624\u6240\u5bfc\u81f4\u7684\u75c7\u72b6\uff0c\u4fe8\u7136\u80bf\u7624\u6cbb\u7597\u7684\u300c\u8001\u914d\u89d2\u300d\u3002<\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

\u76ae\u8d28\u6fc0\u7d20\u5728\u80bf\u7624\u79d1\u5e7f\u6cdb\u5e94\u7528\u7684\u540c\u65f6\uff0c\u8fd1\u4e9b\u5e74\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u4e5f\u9010\u6e10\u5e7f\u6cdb\u7528\u4e8e\u80bf\u7624\u6cbb\u7597\uff0c\u6210\u4e3a\u80bf\u7624\u6cbb\u7597\u7684\u300c\u65b0\u4e3b\u89d2\u300d\u3002<\/span><\/p>\n


<\/p>\n<\/section>\n

\n

\u8003\u8651\u5230\u76ae\u8d28\u6fc0\u7d20\u7684\u514d\u75ab\u6291\u5236\u4f5c\u7528\u4ee5\u53ca\u5bf9 T \u7ec6\u80de\u529f\u80fd\u7684\u6f5c\u5728\u6291\u5236\u4f5c\u7528\uff0c\u662f\u5426\u53ef\u80fd\u5f71\u54cd\u6297 PD-1\/PD-L1 \u5355\u6297\u7684\u7597\u6548\u5462\uff1f
<\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n
\n
\n

2<\/em><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5927\u5242\u91cf\u76ae\u8d28\u6fc0\u7d20\u6216\u5f71\u54cd\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7684\u7597\u6548<\/span><\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

2018 \u5e74 10 \u6708 JOURNAL OF CLINICAL ONCOLOGY\uff08JCO\uff09\u53d1\u8868\u4e86\u4e00\u7bc7\u8861\u91cf PD-1 \u6216 PD-L1 \u6297\u4f53\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u65f6\u4f7f\u7528\u6fc0\u7d20\u5f71\u54cd\u7684\u7814\u7a76\u3002\u8be5\u7814\u7a76\u6c47\u603b\u4e86\u7eaa\u5ff5\u65af\u9686-\u51ef\u7279\u6797\u764c\u75c7\u4e2d\u5fc3\uff08MSKCC\uff09\u548c\u53e4\u65af\u5854\u592b\u9c81\u897f\u764c\u75c7\u4e2d\u5fc3\uff08GRCC\uff09\u63a5\u53d7\u5355\u836f PD-1\/PD-L1 \u6291\u5236\u5242\u6cbb\u7597\u7684 640 \u4f8b\u665a\u671f NSCLC \u60a3\u8005\u75c5\u4f8b\u3002\u4e24\u4e2a\u961f\u5217 MSKCC \u548c GRCC\uff0c\u5747\u53d1\u73b0\u5728 PD-(L)1 \u6297\u4f53\u6cbb\u7597\u4f0a\u59cb\uff0c\u4f7f\u7528\u5f3a\u7684\u677e \u2265 10 mg \u60a3\u8005\u7684 ORR\u3001PFS \u548c OS \u4e0d\u53ca\u4f7f\u7528\uff1c10 mg \u5f3a\u7684\u677e\u5904\u7406\u7684\u60a3\u8005\uff1a<\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\"\u76ae\u8d28\u6fc0\u7d20\u662f\u5426\u4f1a\u5f71\u54cd\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7684\u7597\u6548\uff1f\"<\/section>\n<\/section>\n
\n
\"\u76ae\u8d28\u6fc0\u7d20\u662f\u5426\u4f1a\u5f71\u54cd\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7684\u7597\u6548\uff1f\"<\/section>\n<\/section>\n
\n


<\/p>\n<\/section>\n

\n

\u4f46\u662f\u8be5\u7814\u7a76\u4ec5\u5206\u6790\u4e86\u76ae\u8d28\u6fc0\u7d20\u7684\u5242\u91cf\uff0c\u672a\u8bc4\u4f30\u6fc0\u7d20\u7684\u4f7f\u7528\u65f6\u957f\u3002\u5e76\u4e14\u8be5\u771f\u5b9e\u4e16\u754c\u7814\u7a76\u4e2d\uff0c\u533b\u751f\u5728\u7ed9\u60a3\u8005\u4f7f\u7528\u76ae\u8d28\u6fc0\u7d20\u65f6\u6301\u8c28\u614e\u6001\u5ea6\uff0c\u76ae\u8d28\u6fc0\u7d20\u53ef\u80fd\u88ab\u7528\u4e8e\u9700\u8981\u63a7\u5236\u8111\u8f6c\u79fb\u7684\u60a3\u8005\uff0c\u800c\u8fd9\u4e00\u90e8\u5206\u60a3\u8005\u7684 PFS\u3001OS \u7b49\u6570\u636e\u8868\u73b0\u66f4\u5dee\u3002\u6240\u4ee5\uff0c\u8be5\u7814\u7a76\u7684\u7ed3\u8bba\u8fd8\u9700\u8981\u5176\u4ed6\u7814\u7a76\u52a0\u4ee5\u8bc1\u5b9e\u3002<\/span>
<\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n
\n
\n

3<\/em><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5173\u4e8e\u76ae\u8d28\u6fc0\u7d20\u4e0e\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7597\u6548\u7684\u76f8\u5173\u7814\u7a76<\/span><\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

2018 \u5e74 Pembrolizumab \u4e0e\u7d2b\u6749\u9187\u3001\u5361\u94c2\u8054\u7528\u6cbb\u7597\u80ba\u9cde\u764c\u7684 Keynote-407 \u4e34\u5e8a\u8bd5\u9a8c\u4e2d\uff0c\u4f7f\u7528\u666e\u901a\u7d2b\u6749\u9187\u548c\u65e0\u9700\u6fc0\u7d20\u5904\u7406\u7684\u767d\u86cb\u767d\u7d2b\u6749\u9187\u7ec4\u7684 ORR \u65e0\u663e\u8457\u5dee\u522b\uff0c\u5728\u751f\u5b58\u83b7\u76ca\u65b9\u9762\uff0c\u767d\u86cb\u767d\u7d2b\u6749\u9187\u7ec4 PFS \u751a\u81f3\u4e0d\u53ca\u666e\u901a\u7d2b\u6749\u9187\u7ec4\u3002 <\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

2018 \u5e74 10 \u6708\uff0cSeminars in Oncology \u53d1\u8868\u7684\u4e00\u9879\u9488\u5bf9 157 \u4f8b\u63a5\u53d7\u6297 PD-(L)1 \u6297\u4f53\u6cbb\u7597\u60a3\u8005\u7684\u6587\u7ae0\u53d1\u73b0\uff0c\u514d\u75ab\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\u4e0e PFS \u7684\u6539\u5584\u6709\u5173\uff0c\u8fd9\u79cd\u8054\u7cfb\u6ca1\u6709\u56e0\u5168\u8eab\u76ae\u8d28\u6fc0\u7d20\u7684\u4f7f\u7528\u800c\u6539\u53d8\u3002<\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

2017 \u5e74 3 \u6708 JCO \u53d1\u8868\u7684 Nivolumab\uff08Opdivo\uff0cPD-1 \u6297\u4f53\uff09\u6cbb\u7597\u665a\u671f\u9ed1\u8272\u7d20\u7624\u6db5\u76d6 4 \u4e2a\u4e34\u5e8a\u7814\u7a76\u5171 576 \u4f8b\u60a3\u8005\u7684\u7814\u7a76\u7ed3\u679c\u8ba4\u4e3a\uff0c\u4f7f\u7528 IM\uff08\u5168\u8eab\u76ae\u8d28\u6fc0\u7d20\u6216\u5176\u4ed6\u6291\u5236\u6027\u514d\u75ab\u8c03\u8282\u5242\uff09\u4e0d\u5f71\u54cd ORR\u3002 <\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

2015 \u5e74 10 \u6708 JCO \u53d1\u8868\u4e86\u4e00\u7bc7 MSKCC \u5bf9 Ipilimumab\uff08Yervoy,CTLA-4 \u6297\u4f53\uff09\u6cbb\u7597\u7684 298 \u4f8b\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u514d\u75ab\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u548c\u7c7b\u56fa\u9187\u4f7f\u7528\u5f71\u54cd\u7684\u6587\u7ae0\u3002\u7814\u7a76\u53d1\u73b0\uff0c298 \u540d\u60a3\u8005\u4e2d\uff0c254 \u540d\uff0885%\uff09\u60a3\u8005\u53d1\u751f\u514d\u75ab\u76f8\u5173\u526f\u4f5c\u7528\uff08irAE\uff09\uff0c103 \u540d\u60a3\u8005\uff0835%\uff09\u9700\u8981\u5bf9 irAE \u8fdb\u884c\u5168\u8eab\u6027\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597\u3002\u6570\u636e\u8868\u660e\uff0c\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597\u4e0e\u60a3\u8005 TTF\uff08\u6cbb\u7597\u5931\u8d25\u65f6\u95f4\uff09\u6216 OS \u65e0\u5173\u3002<\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n

2011 \u5e74 Medical Oncology \u6742\u5fd7\u4e5f\u62a5\u9053\u4e86\u6bcf\u5929\u6301\u7eed\u7684\u5168\u8eab\u76ae\u8d28\u6fc0\u7d20\u4f7f\u7528\uff0c\u5728 Ipilimumab \u6cbb\u7597\u540e\u7684\u4e24\u5e74\u591a\u5185\u4e0d\u4f1a\u5f71\u54cd\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u7684\u6301\u7eed\u6d88\u9000\u6848\u4f8b\u3002<\/p>\n<\/section>\n

\n

2007 \u5e74 11 \u6708\uff0cClinical Cancer Research \u6742\u5fd7\u53d1\u8868\u6587\u7ae0\u8ba4\u4e3a\u4f7f\u7528\u9ad8\u5242\u91cf\u7c7b\u56fa\u9187\u6d88\u9664\u6cbb\u7597\u76f8\u5173\u526f\u53cd\u5e94\u4e0d\u4f1a\u5f71\u54cd\u80bf\u7624\u53cd\u5e94\u7684\u6301\u7eed\u65f6\u95f4 (P = 0.23\uff0c\u672a\u8bf4\u660e\u5177\u4f53\u7c7b\u56fa\u9187\u91cf)\u3002 <\/span><\/p>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n

\u603b\u7ed3\u4e0a\u8ff0\u7814\u7a76<\/p>\n<\/section>\n

<\/section>\n<\/section>\n
\n


<\/p>\n<\/section>\n

\n
\n


<\/p>\n<\/section>\n

\n

\u6fc0\u7d20\u4f7f\u7528\u662f\u5426\u4f1a\u5bf9\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7684\u7597\u6548\u4ea7\u751f\u5f71\u54cd\u5c1a\u672a\u6709\u7edf\u4e00\u7ed3\u8bba\u3002\u4f46\u76ee\u524d\u8bc1\u636e\u5747\u663e\u793a\uff0c\u5c0f\u5242\u91cf\u76ae\u8d28\u6fc0\u7d20\u4e0d\u4f1a\u5f71\u54cd\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7684\u7597\u6548\uff0c\u5927\u5242\u91cf\u76ae\u8d28\u6fc0\u7d20\u5bf9\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269\u7597\u6548\u7684\u5f71\u54cd\u5c1a\u4e0d\u786e\u5b9a\u3002\u4e5f\u5c31\u662f\u8bf4\uff0c\u53ea\u8981\u300c\u8001\u914d\u89d2\u300d\u7684\u620f\u4efd\u4e0d\u8981\u8fc7\u591a\uff0c\u5c31\u4e0d\u4f1a\u5f71\u54cd\u300c\u65b0\u4e3b\u89d2\u300d\u80fd\u529b\u7684\u53d1\u6325\u3002<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n


<\/p>\n<\/section>\n

\n
\n
\n
\n
\n
\n
\n
\n

\u53c2\u8003\u6587\u732e\uff1a  <\/strong>
<\/span><\/p>\n

1.Kathryn C. Arbour, Laura Mezquita, Niamh  Long, et al.  Impact of Baseline Steroids on Efficacy of  Programmed  Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non\u2013Small- Lung Cancer. J Clin Oncol 36:2872-2878. <\/span><\/p>\n

2.L. Paz\u2011Ares, A. Luft, D. Vicente, et al. Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small- Lung Cancer. N English J Med 2018 Sep 25. <\/span><\/p>\n

3. Hammad  Shafqat,  Theodore  Gourdin,  Amy  Sion,  Immune-related  adverse  events  are  linked  with  improved progression-free survival in patients receiving anti-PD-1\/PD-L1 therapy. Seminars in Oncology,  October 19, 2018;6:53.  <\/span><\/p>\n

4. Jeffrey S. Weber, F. Stephen Hodi, Jedd D. Wolchok, et al. Safety Profile of Nivolumab Monotherapy: A  Pooled Analysis of Patients with Advanced Melanoma. J Clin Oncol 35:785-792.  <\/span><\/p>\n

5. Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang, et al. Immune-Related Adverse Events, Need for Systemic  Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma  Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193-3198.  <\/span><\/p>\n

6. Kaan Harmankaya, Christa Erasim, Claus Koelblinger, et al. Continuous systemic corticosteroids do not  affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab  therapy. Med Oncol (2011) 28:1140\u20131144.  <\/span><\/p>\n

7. Stephanie G. Downey, Jacob A. Klapper, Franz O. Smith, et al. Prognostic Factors Related to Clinical  Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade. Clin  Cancer Res. 2007 November 15; 13(22 Pt 1): 6681\u20136688.<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n

<\/span><\/p>\n<\/section>\n

\n
\n
\n
\n

\u7f16\u8f91 | \u963f\u7a0b<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u56fe\u7247\u6765\u6e90 | \u7ad9\u9177\u6d77\u6d1b<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"

1 \u76ae\u8d28\u6fc0\u7d20\u662f\u80bf\u7624\u79d1\u7684\u5e38\u7528\u836f \u5bf9\u4e8e\u80bf\u7624\u79d1\uff0c\u76ae\u8d28\u6fc0\u7d20\u662f\u4e00\u79cd\u5f88\u91cd\u8981\u7684\u836f\u7269\uff0c\u5b83\u5177\u6709\u6297\u708e\u3001\u6297\u8fc7\u654f\u3001\u6297\u4f11\u514b\u3001\u6297\u6bd2\u7d20\u3001\u5f71\u54cd […]<\/p>\n","protected":false},"author":1,"featured_media":114816,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/114815"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=114815"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/114815\/revisions"}],"predecessor-version":[{"id":114819,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/114815\/revisions\/114819"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/114816"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=114815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=114815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=114815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}